Capital Analysts LLC Has $217,000 Stock Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Capital Analysts LLC lifted its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 8.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 18,732 shares of the company’s stock after buying an additional 1,537 shares during the period. Capital Analysts LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $217,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Money Concepts Capital Corp bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter worth $25,000. IFP Advisors Inc lifted its position in shares of Global X Genomics & Biotechnology ETF by 121.0% during the 2nd quarter. IFP Advisors Inc now owns 3,521 shares of the company’s stock worth $43,000 after buying an additional 1,928 shares during the last quarter. Advisor Group Holdings Inc. lifted its position in shares of Global X Genomics & Biotechnology ETF by 26.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,916 shares of the company’s stock worth $49,000 after buying an additional 831 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter worth $100,000. Finally, Rockefeller Capital Management L.P. lifted its position in shares of Global X Genomics & Biotechnology ETF by 19.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,200 shares of the company’s stock worth $116,000 after buying an additional 1,493 shares during the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Down 1.1 %

Shares of GNOM stock opened at $9.89 on Thursday. Global X Genomics & Biotechnology ETF has a twelve month low of $8.63 and a twelve month high of $13.33. The company has a market cap of $90.18 million, a P/E ratio of -4.23 and a beta of 1.03. The business has a fifty day simple moving average of $11.34 and a 200 day simple moving average of $10.80.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.